F-Labeled benzylpiperazine derivatives as highly selective ligands for imaging σ receptor with positron emission tomography.

Jiajun Ye,Liang Wang,Winnie Deuther-Conrad,Yuanyuan Chen,Xiaojun Zhang,Jinming Zhang,Yiyun Huang,Peter Brust,Hongmei Jia

DOI: https://doi.org/10.1002/jlcr.3738

2019-01-01

Abstract:We report the design, synthesis, and evaluation of a new series of benzylpiperazine derivatives as selective sigma(1) receptor ligands. All seven ligands possessed low nanomolar affinity for sigma(1) receptors (K-i(sigma(1)) = 0.31-4.19 nM) and high subtype selectivity (K-i(sigma(2))/K-i(sigma(1)) = 50-2448). The fluoroethoxy analogues also exhibited high selectivity toward the vesicular acetylcholine transporter (K-i(VAChT)/K-i(sigma(1)) = 99-18252). The corresponding radiotracers [F-18]13, [F-18]14, and [F-18]16 with high selectivity (K-i(sigma(2))/K-i(sigma(1)) > 100, K-i(VAChT)/K-i(sigma(1)) > 1000) were prepared in 42% to 55% radiochemical yields (corrected for decay), greater than 99% radiochemical purity (RCP), and molar activity of about 120 GBq/mu mol at the end of synthesis (EOS). All three radiotracers showed high initial brain uptake in mouse (8.37-11.48% ID/g at 2 min), which was not affected by pretreatment with cyclosporine A, suggesting that they are not substrates for permeability-glycoprotein (P-gp). Pretreatment with SA4503 or haloperidol resulted in significantly reduced brain uptake (35%-62% decrease at 30 min). In particular, [F-18]16 displayed high brain-to-blood ratios and high in vivo metabolic stability. Although it may not be an optimal neuroimaging agent because of its slow kinetics in the mouse brain, [F-18]16 can serve as a lead compound for further structural modifications to explore new potential radiotracers for sigma(1) receptors.